Navigation Links
AtriCure Reports Record Second Quarter 2008 Financial Results
Date:8/5/2008

8,143,247 9,834,994

Stockholders' equity:

Common stock 14,196 14,132

Additional paid-in capital 104,899,820 103,524,814

Other comprehensive income 57,165 5,286

Accumulated deficit (72,505,779) (67,307,730)

Total stockholders' equity 32,465,402 36,236,502

Total liabilities and

stockholders' equity $40,608,649 $46,071,496

ATRICURE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months Ended June 30,

2008 2007

Cash flows from operating activities:

Net loss $(5,198,047) $(7,089,511)

Adjustments to reconcile net loss to

net cash used in operating activities:

Depreciation and amortization 1,423,711 1,046,280

Loss on disposal of equipment - 6,852

Provision for (benefit from) losses

in accounts receivable 12,397 (99,720)

Share-based compensation expense 1,142,123 882,999

Changes in assets and liabilities,

excluding effects of acquired business:

Accounts receivable (2,192,408) (585,842)

Inventories (556,362) (586,742)

Other current assets 92,879 255,872

Accounts payable and accrued

liabilities (1,234,568) 293,955

Other non-current assets and

liabilities
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results
2. AtriCure Reports First Quarter 2008 Financial Results
3. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
4. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in Miami, FL on ... David A. Ramsay , Chief Financial Officer, will provide a ... the "Investors" section of Halozyme,s corporate website at www.halozyme.com ... days following the event. To access the live webcast, please ...
(Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
(Date:3/3/2015)... Diagnostics Inc. (TSX:V: SQD), a life sciences company that ... advanced microarray diagnostics, today announced it has appointed ... team. In his capacity as CFO he will ... development stage to a commercially successful company including ... market strategy and to secure funding to drive ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3
... responders contained the recent E. coli outbreak quickly, but ... automated system used to identify the disease and coordinate ... information technology played a key role in alerting public ... play an even greater role in future public health ...
... of ethanol from alfalfa or switchgrass isn't nearly as efficient ... grass crops for fuel won't pay, says Paul Weimer. , ... out of biomass from crops such as switchgrass, Weimer is ... large heap of fermentation residue from the ethanol-making process - ...
... Nell Merlino and Laurie Benson may be as different as, ... enriching vision for women entrepreneurs, including those operating in the ... as the eye can see, but the result may be ... want to take their business to the next level. Specifically, ...
Cached Biology Technology:Technology played key role in E. coli alerts 2Technology played key role in E. coli alerts 3Technology played key role in E. coli alerts 4Glue made from ethanol leftovers might be worth more than fuel 2Glue made from ethanol leftovers might be worth more than fuel 3Women entrepreneurs reach for $1M level 2Women entrepreneurs reach for $1M level 3
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... has benefited an,important field of biomedical research, scientists ... of Cryptococcus neoformans, a,fungus whose importance as a ... worldwide epidemic and the increased use of,immunosuppressive therapies.,The ... revealed,differences in the virulence strategies used by C. ...
... and beyond are characterized by extensive segments that ... genes that are closed to gene transcription. Scientists ... is the vital need for genomic stability, for ... other disruptions of the genome's integrity. , Genomic ...
... For the first time, a group of scientists has ... all of the ecosystems on Earth, and the outlook ... 2001, the Millennium Ecosystem Assessment program will issue its ... London, Washington, D.C., Tokyo, Beijing, New Delhi, Brasilia, Cairo, ...
Cached Biology News:Scientists decipher genome of fungus that can cause life-threatening infections 2Scientists decipher genome of fungus that can cause life-threatening infections 3Scientists decipher genome of fungus that can cause life-threatening infections 4Enzyme shown to help protect genomic stability 2Scientists collaborate to assess health of global environment 2Scientists collaborate to assess health of global environment 3
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: